US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

MiniMed (MMED US): Low Passive Fund Flows Due to Low Float

MiniMed Group, Inc. (MMED): Post 180-Days, From Nearly 50% Below IPO to a New Post-IPO High

MiniMed Group, Inc. (MMED): Long-Awaited Medtronic Diabetes Spin-Off Sets Terms for IPO

MiniMed Group, Inc. (MMED): Spin-Off IPO Story of Scale, Recurring Revenue, and Royalty Questions

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>MiniMed priced its IPO at $20, $5 below range, opened below issue, and closed down 7.6%, reflecting weak demand and cautious investor sentiment.</li>
<li>The need to discount the deal highlights a disconnect between underwriters and investors regarding valuation expectations and near-term growth outlook.</li>
<li>Despite the disappointing debut, the reduced valuation level may help stabilize the stock as investors reassess long-term fundamentals.</li>
</ul>


MiniMed priced its IPO at $20, $5 below range, opened below issue, and closed down 7.6%, reflecting weak demand and cautious investor sentiment.
The need to discount the deal highlights a disconnect between underwriters and investors regarding valuation expectations and near-term growth outlook.
Despite the disappointing debut, the reduced valuation level may help stabilize the stock as investors reassess long-term fundamentals.


MiniMed Group, Inc. (MMED): Medtronic Spinoff Falls on First Day Despite Deep IPO Discount